157 related articles for article (PubMed ID: 27287719)
41. Genetic predisposition syndromes: when should they be considered in the work-up of MDS?
Babushok DV; Bessler M
Best Pract Res Clin Haematol; 2015 Mar; 28(1):55-68. PubMed ID: 25659730
[TBL] [Abstract][Full Text] [Related]
42. [Study on the Characteristics of cell cycle and proliferation of CD34+ hematopoietic stem cells in myelodysplastic syndromes].
Shi J; Shao ZH; Liu H; Jia HR; Sun J; Bai J; Wu YH; Jing LP; He GS; Cao YR; Wang XL; Tu MF; Hao YS; Yang TY
Zhonghua Xue Ye Xue Za Zhi; 2004 Nov; 25(11):641-4. PubMed ID: 15634564
[TBL] [Abstract][Full Text] [Related]
43. PAK1 is a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome.
Pandolfi A; Stanley RF; Yu Y; Bartholdy B; Pendurti G; Gritsman K; Boultwood J; Chernoff J; Verma A; Steidl U
Blood; 2015 Aug; 126(9):1118-27. PubMed ID: 26170031
[TBL] [Abstract][Full Text] [Related]
44. Synergistic effect of bortezomib and valproic acid treatment on the proliferation and apoptosis of acute myeloid leukemia and myelodysplastic syndrome cells.
Wang AH; Wei L; Chen L; Zhao SQ; Wu WL; Shen ZX; Li JM
Ann Hematol; 2011 Aug; 90(8):917-31. PubMed ID: 21340723
[TBL] [Abstract][Full Text] [Related]
45. Detection of differential mitotic cell age in bone marrow CD34(+) cells from patients with myelodysplastic syndrome and acute leukemia by analysis of an epigenetic molecular clock DNA signature.
Mossner M; Hopfer O; Nowak D; Baldus CD; Neumann U; Kmetsch A; Benlasfer O; John T; Perka C; Thiel E; Hofmann WK
Exp Hematol; 2010 Aug; 38(8):661-5. PubMed ID: 20399247
[TBL] [Abstract][Full Text] [Related]
46. A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure.
Thepot S; Boehrer S; Seegers V; Prebet T; Beyne-Rauzy O; Wattel E; Delaunay J; Raffoux E; Hunault M; Jourdan E; Chermat F; Sebert M; Kroemer G; Fenaux P; Adès L;
Leuk Res; 2014 Dec; 38(12):1430-4. PubMed ID: 25449687
[TBL] [Abstract][Full Text] [Related]
47. Ribosomal protein S14 silencing inhibits growth of acute myeloid leukemia transformed from myelodysplastic syndromes via activating p53.
Wang L; Luo J; Nian Q; Xiao Q; Yang Z; Liu L
Hematology; 2014 Jun; 19(4):225-31. PubMed ID: 24074450
[TBL] [Abstract][Full Text] [Related]
48. Erlotinib and gefitinib for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a preclinical comparison.
Boehrer S; Adès L; Galluzzi L; Tajeddine N; Tailler M; Gardin C; de Botton S; Fenaux P; Kroemer G
Biochem Pharmacol; 2008 Dec; 76(11):1417-25. PubMed ID: 18617157
[TBL] [Abstract][Full Text] [Related]
49. Molecular pathways in myelodysplastic syndromes and acute myeloid leukemia: relationships and distinctions-a review.
Bernasconi P
Br J Haematol; 2008 Sep; 142(5):695-708. PubMed ID: 18540941
[TBL] [Abstract][Full Text] [Related]
50. Cyclosporine enhances the sensitivity to lenalidomide in MDS/AML in vitro.
He X; Dou A; Feng S; Roman-Rivera A; Hawkins C; Lawley L; Zhang J; Wunderlich M; Mizukawa B; Halene S; Patel A; Fang J
Exp Hematol; 2020 Jun; 86():21-27.e2. PubMed ID: 32437909
[TBL] [Abstract][Full Text] [Related]
51. [Changes and clinical significance of CD8(+) T cell subset in patients with aplastic anemia, myelodysplastic syndrome and acute myeloid leukemia].
Zhang JY; Xu HZ; Yin DM; Feng XM; Sui XH; Cui B; Ma CY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Feb; 21(1):203-8. PubMed ID: 23484720
[TBL] [Abstract][Full Text] [Related]
52. The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation.
Follo MY; Mongiorgi S; Bosi C; Cappellini A; Finelli C; Chiarini F; Papa V; Libra M; Martinelli G; Cocco L; Martelli AM
Cancer Res; 2007 May; 67(9):4287-94. PubMed ID: 17483341
[TBL] [Abstract][Full Text] [Related]
53. Extracellular vesicle miR-7977 is involved in hematopoietic dysfunction of mesenchymal stromal cells via poly(rC) binding protein 1 reduction in myeloid neoplasms.
Horiguchi H; Kobune M; Kikuchi S; Yoshida M; Murata M; Murase K; Iyama S; Takada K; Sato T; Ono K; Hashimoto A; Tatekoshi A; Kamihara Y; Kawano Y; Miyanishi K; Sawada N; Kato J
Haematologica; 2016 Apr; 101(4):437-47. PubMed ID: 26802051
[TBL] [Abstract][Full Text] [Related]
54. Identification and validation of the dopamine agonist bromocriptine as a novel therapy for high-risk myelodysplastic syndromes and secondary acute myeloid leukemia.
Liberante FG; Pouryahya T; McMullin MF; Zhang SD; Mills KI
Oncotarget; 2016 Feb; 7(6):6609-19. PubMed ID: 26735888
[TBL] [Abstract][Full Text] [Related]
55. Eltrombopag can overcome the anti-megakaryopoietic effects of lenalidomide without increasing proliferation of the malignant myelodysplastic syndrome/acute myelogenous leukemia clone.
Tamari R; Schinke C; Bhagat T; Roth M; Braunschweig I; Will B; Steidl U; Verma A
Leuk Lymphoma; 2014 Dec; 55(12):2901-6. PubMed ID: 24650011
[TBL] [Abstract][Full Text] [Related]
56. A phase 1/2 study of rigosertib in patients with myelodysplastic syndromes (MDS) and MDS progressed to acute myeloid leukemia.
Navada SC; Fruchtman SM; Odchimar-Reissig R; Demakos EP; Petrone ME; Zbyszewski PS; Holland JF; Silverman LR
Leuk Res; 2018 Jan; 64():10-16. PubMed ID: 29144985
[TBL] [Abstract][Full Text] [Related]
57. Biology of the bone marrow microenvironment and myelodysplastic syndromes.
Rankin EB; Narla A; Park JK; Lin S; Sakamoto KM
Mol Genet Metab; 2015; 116(1-2):24-8. PubMed ID: 26210353
[TBL] [Abstract][Full Text] [Related]
58. Tyrosine kinase inhibitors for the treatment of acute myeloid leukemia: delineation of anti-leukemic mechanisms of action.
Lainey E; Thépot S; Bouteloup C; Sébert M; Adès L; Tailler M; Gardin C; de Botton S; Baruchel A; Fenaux P; Kroemer G; Boehrer S
Biochem Pharmacol; 2011 Nov; 82(10):1457-66. PubMed ID: 21664897
[TBL] [Abstract][Full Text] [Related]
59. miR-378 inhibits cell growth and enhances apoptosis in human myelodysplastic syndromes.
Kuang X; Wei C; Zhang T; Yang Z; Chi J; Wang L
Int J Oncol; 2016 Nov; 49(5):1921-1930. PubMed ID: 27633496
[TBL] [Abstract][Full Text] [Related]
60. [Study on the transformation from myelodysplastic syndromes into acute leukemias].
Shi J; Shao Z; Liu H; Li K; Song L; Zhang Y; Zheng Y; Chen G; Chu Y; He H; Zhao M; He G; Feng B; Hao Y; Yang T; Yang C
Zhonghua Xue Ye Xue Za Zhi; 2001 Jul; 22(7):351-4. PubMed ID: 11877096
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
